Novo Nordisk | NVO - Debt


Novo Nordisk reported DKK146.38B in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
ANI Pharmaceuticals USD 613.76M 3.28M Mar/2026
Aurora Cannabis CAD 23.86M 76.48M Mar/2026
Bausch Health Companies USD 20.78B 16M Jun/2026
Bristol-Myers Squibb USD 46.43B 711M Mar/2026
Canopy Growth CAD 278.71M 19.38M Mar/2026
Corcept Therapeutics USD 9.64M 3.53M Mar/2026
Drreddys Laboratories INR 77.34B 9.61B Mar/2026
Eli Lilly USD 43.37B 867M Mar/2026
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Merck USD 49.12B 222M Mar/2026
Nektar Therapeutics USD 0 0 Jun/2022
Novartis USD 49.01B 2.02B Jun/2026
Novo Nordisk DKK 118.72B 61.75B Mar/2025
Novo Nordisk DKK 146.38B 27.66B Mar/2026
Pacira USD 363.12M 4.53M Jun/2026
Perrigo USD 3.63B 7.7M Mar/2026
Phibro Animal Health USD 474.17M 730K Sep/2024
Prestige Brands USD 1.05B 33.86M Mar/2026
Sanofi EUR 23.58B 3.56B Jun/2026
Supernus Pharmaceuticals USD 40.17M 733K Jun/2026
Zoetis USD 9.24B 0 Mar/2026